{'fraction_non_alphanumeric': 0.03008130081300813, 'fraction_numerical': 0.032520325203252036, 'mean_word_length': 5.345360824742268, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A phase II trial of ftorafur. Adriamycin and mitomycin‐C (FAM II) in advanced gastric adenocarcinoma

Fifteen patients with advanced gastric cancer were treated with the combination of Ftorafur, Adriamycin and mitomycin‐C (FAM II). Three patients showed partial responses, in five the disease remained stable for at least 3 months and seven showed progression while on treatment. All responding patients showed survival in excess of 12 months. Hematologic toxicity was of only moderate severity. Median white count nadir was 3500 cells/mm3 and median platelet nadir was 187,000 cells/mm3. Four patients had white count nadirs from 2000–2500 cells/mm3 and three had nadirs from 500–1500 cells/mm3; also there were four with platelet nadirs less than 100,000/mm3. However, no drug‐related infections occurred and no platelet transfusions were required. The major nonhematologic toxicities of the regimen were nausea, vomiting, dizziness, vertigo, and rhinorrhea. These toxicities were limiting and resulted in termination of the trial because of poor patient acceptance and the failure of the combination to exhibit a therapeutic advantage over the similar combination (FAM) that employed weekly 5‐fluorouracil in place of Ftorafur.